Knight Therapeutics Announces Launch of Bijuva® in Canada
MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.
- MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA® (estradiol and progesterone) capsules in Canada.
- VMS affects 60% to 80% of women entering menopause1 and are commonly known as hot flashes or flushes and night sweats.
- Knight and TherapeuticsMD signed a license agreement in July 2018 pursuant to which TherapeuticsMD granted Knight the exclusive Canadian commercialization rights to BIJUVA®.
- Under the terms of the license agreement related BIJUVA® in Canada, Knight will pay TherapeuticsMD sales milestone fees and royalties based upon certain aggregate annual sales of BIJUVA® in Canada.